Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 27, 1998

View Archived Issues

Adding SIB-1508Y to antiparkinsonian therapy allows for reduction in dose of L-dopa

Further international approvals, product launches announced for Muse

Algos completes full NDA filing for MorphiDex

Pierre Fabre describes antidepressant compounds with a dual mechanism of action

Novel antiinflammatory/antiallergy agents in the pipeline at Japan Energy

P&G claims alpha2-adrenoceptor agonists with a wide range of potential applications

Access signs licensing agreement with Paladin to market amlexanox in Canada

Pacific Pharmaceuticals and NCI to collaborate in clinical studies of chemosensitizing agent

Biomerica patents H. pylori detection technology

NDA application for Temodal submitted to the FDA

Schwarz, Discovery Therapeutics collaborate on transdermal treatment for Parkinson's disease

Bavarian Nordic becomes first in Europe to conduct clinical trials of cancer gene therapy

Selective alphav/beta3 integrin receptor antagonists from DuPont Pharmaceuticals

Fuji Chemical patents new treatment for kidney disease in diabetic patients

New compounds for reversing MDR reported by Nikken Chemicals

U.S. patent will issue for novel lipid-based gene delivery systems

MOXCON study will test the efficacy of SIRAs in treating heart failure

GG-745: a 5alpha-reductase inhibitor with significant advantages over finasteride

A-131701: a uroselective alpha-adrenergic agent for treatment of BPH

FDA approves first treatment for Crohn's disease

CIBIS-II study results confirm benefits of beta-blockade in heart failure

FDA gives priority review status to COX-2 inhibitor

News from the ACS: LTB4 antagonists for diagnostic use

MMP inhibitors under investigation at Pharmacia & Upjohn

Bristol-Myers Squibb program on beta3-adrenoceptor agonists outlined at ACS

New agent for the prevention of osteoarthritis identified at Roche Bioscience

Glaxo Wellcome presents development candidate GW-311616A

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...